PCOL 824 Final Exam ACTUAL Exam
Questions and CORRECT Answers
serotonin receptor (5HT2C) - CORRECT ANSWER✔✔- serotonin binding activates the
satiety pathway
leptin - CORRECT ANSWER✔✔- -hormone produced in fat cells
-stimulates the satiety pathway and inhibits the hunger pathway
ghrelin - CORRECT ANSWER✔✔- stimulates the NPY pathway (hunger)
amphetamine-like drugs - CORRECT ANSWER✔✔- -short term management of obesity
(appetite suppressant)
ADR: weight rebound
orlistat - CORRECT ANSWER✔✔- irreversible inhibitor of GI lipase (decreases fat
absorption)
ADR: oily spotting, flatulence, fecal urgency, oily stool, decreased absorption of fat soluble
vitamins
phentermine/topiramate - CORRECT ANSWER✔✔- appetite suppressant
*no rebound
ADR: fetal toxicity, SUICIDAL IDEATION, glaucoma, insomnia, increased HR and bp,
DSYGEUSIA (metal taste disturbance)
lorcaserin - CORRECT ANSWER✔✔- selective 5-HT2C receptor agonist
*rebound effect and weight loss plateau
ADR: HA, dizziness, nausea
bupropion/naltrexone - CORRECT ANSWER✔✔- antidepressant and opiate receptor
antagonist
, ADR: insomnia, SUICIDAL IDEATION, increased HR and bp, nausea, HA, dizziness, dry
mouth
*contraindicated in pts with opioid dependency
liraglutide - CORRECT ANSWER✔✔- GLP-1 mimetic
ADR: diarrhea, pancreatitis, N/V
cellulose-citric acid polymer - CORRECT ANSWER✔✔- hydrogel that takes up water and
expands with the stomach
*medical device
ADR: diarrhea, abdominal pain/distension, constipation
fenfluramine/dexfenfluramine - CORRECT ANSWER✔✔- *taken off the market
MOA: activation of 5-HT2C receptors
ADR: cardiac valvular fibrosis
phenylpropanolamine - CORRECT ANSWER✔✔- *taken off the market
MOA: amphetamine-like appetite suppressant
ADR: increased risk of hemorrhagic stroke
sibutramine - CORRECT ANSWER✔✔- *taken off the market
MOA: inhibitor of NEP and serotonin reuptake causing increased activation of 5-HT2C
ADR: increased HR and BP, serotonin syndrome
rimonabant - CORRECT ANSWER✔✔- *taken off the market
MOA: antagonist of cannabinoid CBI receptor (inhibits the hunger pathway-NPY)
ADR: psychiatric effects (depression)
pramlintide - CORRECT ANSWER✔✔- amylin analog
*decreases glucagon release, slows rate of gastric emptying, increases satiety
Questions and CORRECT Answers
serotonin receptor (5HT2C) - CORRECT ANSWER✔✔- serotonin binding activates the
satiety pathway
leptin - CORRECT ANSWER✔✔- -hormone produced in fat cells
-stimulates the satiety pathway and inhibits the hunger pathway
ghrelin - CORRECT ANSWER✔✔- stimulates the NPY pathway (hunger)
amphetamine-like drugs - CORRECT ANSWER✔✔- -short term management of obesity
(appetite suppressant)
ADR: weight rebound
orlistat - CORRECT ANSWER✔✔- irreversible inhibitor of GI lipase (decreases fat
absorption)
ADR: oily spotting, flatulence, fecal urgency, oily stool, decreased absorption of fat soluble
vitamins
phentermine/topiramate - CORRECT ANSWER✔✔- appetite suppressant
*no rebound
ADR: fetal toxicity, SUICIDAL IDEATION, glaucoma, insomnia, increased HR and bp,
DSYGEUSIA (metal taste disturbance)
lorcaserin - CORRECT ANSWER✔✔- selective 5-HT2C receptor agonist
*rebound effect and weight loss plateau
ADR: HA, dizziness, nausea
bupropion/naltrexone - CORRECT ANSWER✔✔- antidepressant and opiate receptor
antagonist
, ADR: insomnia, SUICIDAL IDEATION, increased HR and bp, nausea, HA, dizziness, dry
mouth
*contraindicated in pts with opioid dependency
liraglutide - CORRECT ANSWER✔✔- GLP-1 mimetic
ADR: diarrhea, pancreatitis, N/V
cellulose-citric acid polymer - CORRECT ANSWER✔✔- hydrogel that takes up water and
expands with the stomach
*medical device
ADR: diarrhea, abdominal pain/distension, constipation
fenfluramine/dexfenfluramine - CORRECT ANSWER✔✔- *taken off the market
MOA: activation of 5-HT2C receptors
ADR: cardiac valvular fibrosis
phenylpropanolamine - CORRECT ANSWER✔✔- *taken off the market
MOA: amphetamine-like appetite suppressant
ADR: increased risk of hemorrhagic stroke
sibutramine - CORRECT ANSWER✔✔- *taken off the market
MOA: inhibitor of NEP and serotonin reuptake causing increased activation of 5-HT2C
ADR: increased HR and BP, serotonin syndrome
rimonabant - CORRECT ANSWER✔✔- *taken off the market
MOA: antagonist of cannabinoid CBI receptor (inhibits the hunger pathway-NPY)
ADR: psychiatric effects (depression)
pramlintide - CORRECT ANSWER✔✔- amylin analog
*decreases glucagon release, slows rate of gastric emptying, increases satiety
